Community Health plans $12M east-side medical complex
Construction is set to begin soon on Community Health Pavilion, a three-story, 55,000-square-foot medical building to be built on six acres at 7910 E. Washington St.
Health Care & Insurance
Articles
WellPoint headquarters snags $42M
Massachusetts-based Franklin Street Properties acquired the Monument Circle headquarters of insurance giant WellPoint Inc. late in 2010 for $42 million—a rich $196 per square foot—from an affiliate of locally based HDG Mansur.
Endocyte prices IPO stock
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
LAMKIN: Health care reform is opportunity to reorganize services
Indiana should take advantage of the opportunity to build a comprehensive exchange.
By wide margin, Anthem still city’s largest insurer
Anthem Blue Cross and Blue Shield’s share of the Indianapolis area has leveled off, even though it still insures more than half the commercial market—or three times as much as its nearest competitor.
Can video games be good for your health?
Local companies are embedding stealthy video messages for high school and college students.
UPDATE: Judge adds probation to Guidant device plea deal
A Minnesota judge has signed off on a plea agreement that calls for Boston Scientific Corp.'s Guidant unit to pay $296 million for failing to properly disclose changes made to some implantable heart devices, but added three years of probation to the deal.
Roche back in court as partner looks to sell to competitor
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
Guidant to appear in federal court for sentencing
Boston Scientific Corp.'s Guidant unit hopes to end a criminal case accusing it of failing to properly disclose changes made to some implantable heart devices when it appears in court Wednesday.
Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
Q&A: Derek Bang
Derek Bang, practice leader of health care advisory services at the Crowe Horwath accounting firm in Indianapolis, spent a week in March studying health care in the United Kingdom, especially its universal health care program. He was surprised by the “daily barrage of criticism” he heard about the National Health Service, but also found that the United Kingdom and United States face very similar issues when it comes to constraining growth in health care costs.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Lilly agrees to pay up to $1.2B for diabetes drugs
A complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
Lilly partner moves up timetable for diabetes drug
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.
Bill would let Indiana pharmacies collect old meds
A bill authored by Republican Rep. Kevin Mahan of Hartford City would revise state law so that pharmacies could accept unused prescription drugs from customers and dispose of them securely and safely.
Closed dental company working to transfer patients
Citing cash-flow problems, Allcare Dental and Dentures shut down operations in 14 states, including Indiana, last week.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
IndyCar deal creates series-branded insurance plan
Open-wheel race series signs three-year sponsorship pact with Dallas-based Global Corporate Alliance.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.